Radiopharmaceuticals – our new study reveals trends, R&D progress, and predicted revenues
Where is the Radiopharmaceutical market heading? If you are involved in this sector you must read this brand new report. Visiongain’s report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.
Discover How to Stay Ahead
Our 234-page report provides 193 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biosimulation market. See how to exploit the opportunities.
Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are forecasts for 6 Applications, 11 Radioisotopes, 2 Sources, and 4 end-users
Radiopharmaceuticals, by Application
• Oncology
• Cardiology
• Gastroenterology
• Neuroendocrinology
• Neurology
• Nephrology
• Others
Radiopharmaceuticals, by Radioisotope
• Tec 99
• Fluorine 18
• Iodine131
• Lutetium 177
• Yttrium 90
• Gallium 68
• Gallium 67
• Rubidium 82
• Iodine 123
• Iodine 125
• Indium 111
• Others
Radiopharmaceuticals, by Source
• Cyclotrons
• Nuclear Reactors
Radiopharmaceuticals, by End User
• Hospitals
• Diagnostic Imaging Centres
• Ambulatory Surgical Centres
• Cancer Research Institutes
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 6 regional and 21 leading national markets:
• North America:
• The US
• Canada
• Latin America:
• Brazil
• Mexico
• Rest of Latin America
• Western Europe:
• Germany
• UK
• Italy
• Spain
• France
• Nordic Countries
• Benelux
• Rest of Western Europe
• Eastern Europe:
• Russia
• Poland
• Rest of Eastern Europe
• APAC:
• Japan
• China
• India
• Australia & New Zealand
• ASEAN countries
• Rest of Asia-Pacific
• MEA:
• South Africa
• GCC
• North African countries
• Rest of MEA
The report also includes profiles and historical results for some of the leading companies in the radiopharmaceutical market, with a focus on the radiopharmaceutical segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for radiopharmaceutical will surpass $5bn in 2017, our work calculates. We predict strong revenue growth through to 2027. The increasing cost of drug development and increasing need for simulation software to reduce
Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Biosimulation Market report helps you
In summary, our 234-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the Biosimulation market and 4 different segmentations, with forecasts for 6 Applications, 11 Radioisotopes, 2 Sources and 4 End Users – discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for 21 of the leading national markets – US, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Benelux, Poland, Russia, Japan, China, India, Australia & New Zealand, ASEAN, GCC, South Africa, Northern African Countries
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market – including company profiles and forecasts for 9 companies’ biosimulation segment revenues to 2027
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Biosimulation market and leading companies. You will find data, trends and predictions.
Get our report today The Global Radiopharmaceutical Market Forecast 2017-2027: Revenue Prospects by Application (Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Neurology, Nephrology, Others) Radioisotope (Tc-99, F-18, I-131, Lu-177, Y-90, Ga-68, Ga-67, Rb-82, I-123, I-125, I-111, Others), Source (Cyclotrons, Nuclear Reactors), End User (Hospitals, Diagnostic Imaging Centres, Ambulatory Surgical Centres, Cancer Research Institutes) and Geography. Avoid missing out – get our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Introduction
1.2 Why You Should Read This Report
1.3 Key Questions Answered by This Analytical Report
1.4 Who is This Report For?
1.5 Methodology
1.6 Frequently Asked Questions (FAQ)
1.7 Associated Visiongain Reports
1.8 About Visiongain
2. Radiopharmaceutical Market Overview
2.1 Introduction
2.1.1 Market Definition
2.1.2 Market Taxonomy
2.2 Global Radiopharmaceutical Market Size and Forecast
2.3 Market Dynamics
2.3.1 Global Radiopharmaceutical Market: Drivers
2.3.1.1 Evolution towards Centralized Pharmacies
2.3.1.2 Increasing Number of PET and SPECT Scanners Globally
2.3.1.3 Minimizing the Dose in Paediatric Nuclear Imaging
2.3.1.4 Consolidation of Supply Chain
2.3.1.5 Growing Interest of Investors of Conventional Pharmaceutical Industries in the Therapeutic Area
2.3.1.6 Russian Supply Initiative for Mo-99
2.3.1.7 Increasing Domestic Radiopharmaceutical Production
2.3.1.8 Rising Incidence of Cancer and Cardiovascular Diseases
2.3.1.9 Diagnostics Remain a Key Focus of Radiopharmaceuticals Companies
2.3.1.10 Advancement in Radiotracers
2.3.2 Global Radiopharmaceutical Market: Restraints
2.3.2.1 Price Sensitivity and Lack of Specified Guidelines
2.3.2.2 Shorter Half Life of Radiopharmaceuticals Devices
2.3.2.3 Closing of Ageing Research Reactors Worldwide
2.3.3 Global Radiopharmaceutical Market: Opportunity
2.3.3.1 Alternative Diagnostic Radiopharmaceuticals Solutions
2.3.3.2 Lutetium 177
2.3.4 Global Radiopharmaceutical Market: Trends
2.3.4.1 Increasing focus of Manufacturers towards Diagnostic Tracers
2.3.4.2 Increasing Penetration of Radio-therapeutics
2.3.4.3 Fluoro-deoxy glucose (FDG)
2.3.4.4 Gallium-68
2.3.4.5 Nuclear pharmacies
2.3.4.6 Shortage of molybdenum-99/technetium-99m
2.4 Key Regulations
3. Global Radiopharmaceutical Market Analysis and Forecast, By Application
3.1 Introduction
3.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Application
3.2 Global Radiopharmaceutical Market Size and Forecast, By Application
3.2.1 Oncology Segment
3.2.2 Cardiology Segment
3.2.3 Gastroenterology
3.2.4 Neuroendocrinology
3.2.5 Neurology
3.2.6 Nephrology
3.2.7 Others
3.3 Global Radiopharmaceutical Market Attractiveness Index, By Application
4. Global Radiopharmaceutical Market Analysis and Forecast, By Radioisotope
4.1 Introduction
4.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Radioisotope
4.2 Global Radiopharmaceutical Market Size and Forecast, By Radioisotope
4.2.1 Tec. 99 Segment
4.2.2 F18 Segment
4.2.3 Iodine 131 Segment
4.2.4 Lutetium 177 Segment
4.2.5 Yttrium 90 Segment
4.2.6 Gallium 68 Segment
4.2.7 Gallium 67 Segment
4.2.8 Rubidium 82 Segment
4.2.9 Iodine 123 Segment
4.2.10 Iodine 125 Segment
4.2.11 Indium 111 Segment
4.2.12 Others Segment
4.3 Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope
5. Global Radiopharmaceutical Market Analysis and Forecast, By Source
5.1 Introduction
5.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Source
5.2 Global Radiopharmaceutical Market Size and Forecast, By Source
5.2.1 Cyclotrons Segment
5.2.2 Nuclear Reactors Segment
5.3 Global Radiopharmaceutical Market Attractiveness Index, By Source
6. Global Radiopharmaceutical Market Analysis and Forecast, By End User
6.1 Introduction
6.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By End User
6.2 Global Radiopharmaceutical Market Size and Forecast, By End User
6.2.1 Hospitals Segment
6.2.2 Diagnostic Imaging Centres Segment
6.2.3 Ambulatory Surgical Centres Segment
6.2.4 Cancer Research Institute Segment
6.3 Global Radiopharmaceutical Market Attractiveness Index, By End User
7. Global Radiopharmaceutical Market Analysis and Forecast, By Region
7.1 Introduction
7.1.1 Global Radiopharmaceutical Market, Annual Growth Rate Comparison, By Region
7.2 Global Radiopharmaceutical Market Size and Forecast, By Region
7.2.1 North America
7.2.2 Latin America
7.2.3 Western Europe
7.2.4 Eastern Europe
7.2.5 Asia Pacific
7.2.6 MEA
7.3 Global Radiopharmaceutical Market Attractiveness Index, By Region
8. North America Radiopharmaceutical Market Analysis and Forecast, 2016–2027
8.1 Introduction
8.1.1 North America Radiopharmaceutical Market
8.1.2 North America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
8.2 North America Radiopharmaceutical Market Size and Forecast, By Country
8.2.1 The U.S. Radiopharmaceutical Market
8.2.2 Canada Radiopharmaceutical Market
8.3 North America Radiopharmaceutical Market Size and Forecast, By Application
8.4 North America Radiopharmaceutical Market Size and Forecast, By Radioisotope
8.5 North America Radiopharmaceutical Market Size and Forecast, By Source
8.6 North America Radiopharmaceutical Market Size and Forecast, By End User
8.7 North America Radiopharmaceutical Market Attractiveness Index
8.7.1 North America Radiopharmaceutical Market Attractiveness Index, By Country
8.7.2 North America Radiopharmaceutical Market Attractiveness Index, By Application
8.7.3 North America Radiopharmaceutical Market Attractiveness Index, By Radioisotope
8.7.4 North America Radiopharmaceutical Market Attractiveness Index, By Source
8.7.5 North America Radiopharmaceutical Market Attractiveness Index, By End User
9. Latin America Radiopharmaceutical Market Analysis and Forecast, 2016–2027
9.1 Introduction
9.1.1 Latin America Radiopharmaceutical Market
9.1.2 Latin America Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
9.2 Latin America Radiopharmaceutical Market Size and Forecast, By Country
9.2.1 Brazil Radiopharmaceutical Market
9.2.2 Mexico Radiopharmaceutical Market
9.2.3 Rest of Latin America Radiopharmaceutical Market
9.3 Latin America Radiopharmaceutical Market Size and Forecast, By Application
9.4 Latin America Radiopharmaceutical Market Size and Forecast, By Radioisotope
9.5 Latin America Radiopharmaceutical Market Size and Forecast, By Source
9.6 Latin America Radiopharmaceutical Market Size and Forecast, By End User
9.7 Latin America Radiopharmaceutical Market Attractiveness Index
9.7.1 Latin America Radiopharmaceutical Market Attractiveness Index, By Country
9.7.2 Latin America Radiopharmaceutical Market Attractiveness Index, By Application
9.7.3 Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope
9.7.4 Latin America Radiopharmaceutical Market Attractiveness Index, By Source
9.7.5 Latin America Radiopharmaceutical Market Attractiveness Index, By End User
10. Western Europe Radiopharmaceutical Market Analysis and Forecast, 2017–2027
10.1 Introduction
10.1.1 Western Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
10.2 Western Europe Radiopharmaceutical Market Size and Forecast, By Country
10.2.1 U.K. Radiopharmaceutical Market
10.2.2 France Radiopharmaceutical Market
10.2.3 Germany Radiopharmaceutical Market
10.2.4 Italy Radiopharmaceutical Market
10.2.5 Spain Radiopharmaceutical Market
10.2.6 Nordic Radiopharmaceutical Market
10.2.7 Benelux Radiopharmaceutical Market
10.2.8 Rest of Western Europe Radiopharmaceutical Market
10.3 Western Europe Radiopharmaceutical Market Size and Forecast, By Application
10.4 Western Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope
10.5 Western Europe Radiopharmaceutical Market Size and Forecast, By Source
10.6 Western Europe Radiopharmaceutical Market Size and Forecast, By End User
10.7 Western Europe Radiopharmaceutical Market Attractiveness Index
10.7.1 Western Europe Radiopharmaceutical Market Attractiveness Index, By Country
10.7.2 Western Europe Radiopharmaceutical Market Attractiveness Index, By Application
10.7.3 Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope
10.7.4 Western Europe Radiopharmaceutical Market Attractiveness Index, By Source
10.7.5 Western Europe Radiopharmaceutical Market Attractiveness Index, By End User
11. Eastern Europe Radiopharmaceutical Market Analysis and Forecast, 2017–2027
11.1 Introduction
11.1.1 Eastern Europe Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
11.2 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Country
11.2.1 Russia Radiopharmaceutical Market
11.2.2 Poland Radiopharmaceutical Market
11.2.3 Rest of Eastern Europe Radiopharmaceutical Market
11.3 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Application
11.4 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Radioisotope
11.5 Eastern Europe Radiopharmaceutical Market Size and Forecast, By Source
11.6 Eastern Europe Radiopharmaceutical Market Size and Forecast, By End User
11.7 Eastern Europe Radiopharmaceutical Market Attractiveness Index
11.7.1 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country
11.7.2 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application
11.7.3 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope
11.7.4 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source
11.7.5 Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User
12. Asia Pacific Radiopharmaceutical Market Analysis and Forecast, 2017–2027
12.1 Introduction
12.1.1 Asia Pacific Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
12.1.2 Asia Pacific Radiopharmaceutical Market, BPS Analysis, By Country
12.2 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Country
12.2.1 China Radiopharmaceutical Market
12.2.2 India Radiopharmaceutical Market
12.2.3 Australia and New Zealand Radiopharmaceutical Market
12.2.4 ASEAN Radiopharmaceutical Market
12.2.5 Japan Radiopharmaceutical Market
12.2.6 Rest of Asia Pacific Radiopharmaceutical Market
12.3 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Application
12.4 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Radioisotope
12.5 Asia Pacific Radiopharmaceutical Market Size and Forecast, By Source
12.6 Asia Pacific Radiopharmaceutical Market Size and Forecast, By End User
12.7 Asia Pacific Radiopharmaceutical Market Attractiveness Index
12.7.1 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country
12.7.2 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application
12.7.3 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope
12.7.4 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source
12.7.5 Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User
13. MEA Radiopharmaceutical Market Analysis and Forecast, 2017–2027
13.1 Introduction
13.1.1 MEA Radiopharmaceutical Market, Annual Growth Rate Comparison, By Country
13.2 MEA Radiopharmaceutical Market Size and Forecast, By Country
13.2.1 GCC Countries Radiopharmaceutical Market
13.2.2 South Africa Radiopharmaceutical Market
13.2.3 North Africa Radiopharmaceutical Market
13.2.4 Rest of MEA Radiopharmaceutical Market
13.3 MEA Radiopharmaceutical Market Size and Forecast, By Application
13.4 MEA Radiopharmaceutical Market Size and Forecast, By Radioisotope
13.5 MEA Radiopharmaceutical Market Size and Forecast, By Source
13.6 MEA Radiopharmaceutical Market Size and Forecast, By End User
13.7 MEA Radiopharmaceutical Market Attractiveness Index
13.7.1 MEA Radiopharmaceutical Market Attractiveness Index, By Country
13.7.2 MEA Radiopharmaceutical Market Attractiveness Index, By Application
13.7.3 MEA Radiopharmaceutical Market Attractiveness Index, By Radioisotope
13.7.4 MEA Radiopharmaceutical Market Attractiveness Index, By Source
13.7.5 MEA Radiopharmaceutical Market Attractiveness Index, By End User
14. Leading Companies in the Radiopharmaceutical Market
14.1 Competition Dashboard
14.2 Company Share Analysis
14.3 Company Profiles
14.3.1 Siemens AG
14.3.1.1 Basic Information
14.3.1.2 Company Overview
14.3.1.3 Product Offering
14.3.1.4 Financial Statements
14.3.1.5 Company Strategy
14.3.1.6 Key Developments
14.3.2 Eckert & Ziegler
14.3.2.1 Basic Information
14.3.2.2 Company Overview
14.3.2.3 Product Offering
14.3.2.4 Financial Statements
14.3.2.5 Key Developments
14.3.2.6 Company Strategy
14.3.3 Lantheus Medical Imaging, Inc.
14.3.3.1 Basic Information
14.3.3.2 Company Overview
14.3.3.3 Product Offering
14.3.3.4 Financial Statements
14.3.3.5 Key Developments
14.3.3.6 Company Strategy
14.3.4 Cardinal Health, Inc.
14.3.4.1 Basic Information
14.3.4.2 Company Overview
14.3.4.3 Product Offering
14.3.4.4 Financial Statements
14.3.4.5 Key Developments
14.3.4.6 Company Strategy
14.3.5 Bayer AG
14.3.5.1 Basic Information
14.3.5.2 Company Overview
14.3.5.3 Product Offering
14.3.5.4 Financial Statements
14.3.5.5 Key Developments
14.3.5.6 Company Strategy
14.3.6 Bracco Imaging S.P.A
14.3.6.1 Basic Information
14.3.6.2 Company Overview
14.3.6.3 Product Offering
14.3.6.4 Key Developments
14.3.6.5 Company Strategy
14.3.7 Nordion Inc.
14.3.7.1 Basic Information
14.3.7.2 Company Overview
14.3.7.3 Product Offering
14.3.7.4 Key Developments
14.3.7.5 Company Strategy
14.3.8 Advanced Accelerator Applications S.A.
14.3.8.1 Basic Information
14.3.8.2 Company Overview
14.3.8.3 Product Offering
14.3.8.4 Financial Statements
14.3.8.5 Key Developments
14.3.8.6 Company Strategy
14.3.9 Mallinckrodt PLC
14.3.9.1 Basic Information
14.3.9.2 Company Overview
14.3.9.3 Product Offering
14.3.9.4 Financial Statements
14.3.9.5 Key Developments
14.4 Other Companies of Interest in the Radiopharmaceutical Market
15. Conclusion
16. Glossary
Visiongain Report Sales Order Form
Associated Visiongain Reports
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
List of Figures
Figure 2.1 Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2015–2027
Figure 3.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015–2027
Figure 3.2: Global Radiopharmaceutical Market AGR (%) Comparison, By Application Segment, 2015–2027
Figure 3.4: Global Oncology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 3.5: Global Cardiology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 3.6: Global Gastroenterology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Segment, 2014–2027
Figure 3.7: Global Neuroendocrinology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 3.8: Global Neurology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 3.9: Global Nephrology Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 3.10: Global Other Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 3.11: Global Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
Figure 4.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Radioisotope Segment, 2015–2027
Figure 4.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Tec. 99 Segment, 2014–2027
Figure 4.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By F18 Segment, 2014–2027
Figure 4.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 131 Segment, 2014–2027
Figure 4.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Lutetium 177 Segment, 2014–2027
Figure 4.6: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Yttrium 90 Segment, 2014–2027
Figure 4.7: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 68 Segment, 2014–2027
Figure 4.8: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Gallium 67 Segment, 2014–2027
Figure 4.9: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rubidium 82 Segment, 2014–2027
Figure 4.10: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 123 Segment, 2014–2027
Figure 4.11: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Iodine 125 Segment, 2014–2027
Figure 4.12: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Indium 111 Segment, 2014–2027
Figure 4.13: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Others Segment, 2014–2027
Figure 4.14: Global Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
Figure 5.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Source Segment, 2015–2027
Figure 5.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cyclotrons Segment, 2014–2027
Figure 5.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Nuclear Reactors Segment, 2014–2027
Figure 5.4: Global Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
Figure 6.1: Global Radiopharmaceutical Market AGR (%) Comparison, By End User Segment, 2015–2027
Figure 6.2: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Hospitals Segment, 2014–2027
Figure 6.3: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Diagnostic Imaging Centres Segment, 2014–2027
Figure 6.4: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Ambulatory Surgical Centres Segment, 2014–2027
Figure 6.5: Global Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Cancer Research Institute Segment, 2014–2027
Figure 6.6: Global Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
Figure 7.1: Global Radiopharmaceutical Market AGR (%) Comparison, By Region, 2015–2027
Figure 7.2: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 7.3: Latin American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 7.4: Western European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 7.5: Eastern European Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 7.6: Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 7.7: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 7.8: Global Radiopharmaceutical Market Attractiveness Index, By Region, 2017–2027
Figure 8.1: North American Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 8.2: North American Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
Figure 8.3: US Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 8.4: Canadian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 8.5: North American Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
Figure 8.6: North American Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
Figure 8.7: North American Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
Figure 8.8: North American Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
Figure 8.9: North American Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
Figure 9.1: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 9.2: Latin America Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
Figure 9.3: Brazilian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 9.4: Mexican Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 9.5: Latin America Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By Rest of Latin America, 2014–2027
Figure 9.6: Latin America Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
Figure 9.7: Latin America Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
Figure 9.8: Latin America Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
Figure 9.9: Latin America Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
Figure 9.10: Latin America Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
Figure 10.1: Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 10.2: Western Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
Figure 10.3: UK Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 10.4: French Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 10.5: German Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 10.6: Italian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 10.7: Spanish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 10.8: Nordic Radiopharmaceutical Market Value (US$m) Forecast and AGR (%),2014–2027
Figure 10.9: Benelux Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 10.10: Rest of Western Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 10.11: Western Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
Figure 10.12: Western Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
Figure 10.13: Western Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
Figure 10.14: Western Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
Figure 10.15: Western Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
Figure 11.1: Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 11.2: Eastern Europe Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
Figure 11.3: Russian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 11.4: Polish Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 11.5: Rest of Eastern Europe Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 11.6: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
Figure 11.7: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
Figure 11.8: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
Figure 11.9: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
Figure 11.10: Eastern Europe Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
Figure 12.1 Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 12.2: Asia Pacific Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
Figure 12.3: Chinese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 12.4: Indian Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 12.5: Australia and New Zealand Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 12.6: ASEAN Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 12.7: Japanese Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 12.8: Rest of Asia Pacific Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 12.9: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
Figure 12.10: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
Figure 12.11: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
Figure 12.12: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
Figure 12.13: Asia Pacific Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
Figure 13.1: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 13.2: MEA Radiopharmaceutical Market AGR (%) Comparison, By Country, 2015–2027
Figure 13.3: MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), By GCC Countries, 2014–2027
Figure 13.4: South African Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 13.5: North African Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 13.6: Rest of MEA Radiopharmaceutical Market Value Forecast (US$m) and AGR (%), 2014–2027
Figure 13.7: MEA Radiopharmaceutical Market Attractiveness Index, By Country, 2017–2027
Figure 13.8: MEA Radiopharmaceutical Market Attractiveness Index, By Application, 2017–2027
Figure 13.9: MEA Radiopharmaceutical Market Attractiveness Index, By Radioisotope, 2017–2027
Figure 13.10: MEA Radiopharmaceutical Market Attractiveness Index, By Source, 2017–2027
Figure 13.11: MEA Radiopharmaceutical Market Attractiveness Index, By End User, 2017–2027
Figure 14.1: Leading Radiopharmaceutical Companies, By Market Share (%), 2016
Figure 14.2: Siemens Segment Percentage Split (2016)
Figure 14.3: Siemens Geographical Percentage Split (2016)
Figure 14.4: Eckert & Ziegler Segment Percentage Split
Figure 14.5: Eckert & Ziegler Geographic Percentage Split
Figure 14.6: Lantheus Medical Imaging, Inc. Segment Percentage Split
Figure 14.7: Lantheus Medical Imaging, Inc. Geographical Percentage Split
Figure 14.8: Cardinal Health, Inc. Segment Percentage Split
Figure 14.9: Cardinal Health, Inc. Geographical Percentage Split
Figure 14.10: Bayer AG Segment Percentage Split
Figure 14.11: Bayer AG Segment Geographical Percentage Split
Figure 14.12: Advanced Accelerator Applications S.A., Segment Percentage Split
Figure 14.13: Advanced Accelerator Applications S.A., Geographical Percentage Split
Figure 14.14: Mallinckrodt PLC Segment Percentage Split
Figure 14.15: Mallinckrodt PLC Geographical Percentage Split
Figure 15.1 Radiopharmaceutical Market Drivers and Restraints
List of Tables
Table 2.1 Global Radiopharmaceutical Market Segmentation
Table 3.1: Global Radiopharmaceutical Market Value (US$m) Forecast, By Radioisotope, 2016–2027
Table 3.2 Global Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 4.1: Global Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 4.1: Global Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 5.1: Global Radiopharmaceutical Market Value (US$m) Forecast, By Radioisotope, 2016–2027
Table 6.1: Global Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 7.1: Global Radiopharmaceutical Market Forecast, By Region ($m, AGR%, CAGR%) 2016-2027
Table 8.1: North American Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 8.2: North American Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 8.2: North American Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 8.3: North American Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 8.4: North American Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 9.1: Latin America Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 9.2: Latin America Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 9.3: Latin America Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 9.3: Latin America Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 9.4: Latin America Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 9.5: Latin America Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2017
Table 10.1: Western Europe Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 10.2: Western Europe Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 10.3: Western Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 10.3: Western Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 10.4: Western Europe Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 10.5: Western Europe Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 11.1: Eastern Europe Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 11.2: Eastern Europe Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 11.3: Eastern Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 11.3: Eastern Europe Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 11.4: Eastern Europe Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 11.5: Eastern Europe Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 12.1: Asia Pacific Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 12.2: Asia Pacific Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 12.3: Asia Pacific Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 12.3: Asia Pacific Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 12.4: Asia Pacific Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 12.5: Asia Pacific Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 13.1: MEA Radiopharmaceutical Market Forecast, ($m, AGR%) 2016-2027
Table 13.2: MEA Radiopharmaceutical Market Forecast, By Application ($m, AGR%) 2016-2027
Table 13.3: MEA Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027
Table 13.3: MEA Radiopharmaceutical Market Forecast, By Radioisotopes ($m, AGR%) 2016-2027 (continued)
Table 13.4: MEA Radiopharmaceutical Market Forecast, By Source ($m, AGR%) 2016-2027
Table 13.5: MEA Radiopharmaceutical Market Forecast, By End User ($m, AGR%) 2016-2027
Table 14.1: Radiopharmaceutical Market Competitive Overview
Table 14.2: Siemens AG Overview, 2016
Table 14.3: Siemens AG Financial Overview, 2014-2016
Table 14.4: Siemens Recent Developments
Table 14.5: Eckert & Ziegler Overview, 2016
Table 14.7: Eckert & Ziegler Recent Developments
Table 14.8: Lantheus Medical Imaging, Inc., Overview, 2016
Table 14.9 Lantheus Medical Imaging, Inc., Financial Overview 2013-2015
Table 14.10: Lantheus Medical Imaging, Inc., Recent Developments
Table 14.13: Cardinal Health Inc. Recent Developments
Table 14.14: Bayer AG, Overview, 2016
Table 14.15: Bayer AG, Financial Overview, 2014-2016
Table 14.16: Bayer AG Recent Developments
Table 14.17: Bracco Imaging S.P.A, Overview, 2016
Table 14.18: Bracco Imaging S.P.A, Recent Developments
Table 14.19: Nordion Inc., Overview, 2016
Table 14.20: Siemens Recent Developments
Table 14.21: Advanced Accelerator Applications S.A., Overview, 2016
Table 14.22: Advanced Accelerator Applications S.A., Financial Overview, 2013-2015
Table 14.23: Advanced Accelerator Applications S.A. Recent Developments
Table 14.24: Mallinckrodt PLC, Overview, 2016
Table 14.25: Mallinckrodt PLC, Overview, 2016
Table 14.26: Siemens Recent Developments
Table 14.27: Other Companies of Interest in the Radiopharmaceutical Market
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
